title: Enamel matrix derivative proteins for the treatment of proximal class II furcation involvements: a prospective 24-month randomized clinical trial.
abstract: OBJECTIVE
  This study aimed to evaluate the response of proximal furcations treated with enamel matrix derivative proteins (EMD) in a 24-month follow-up.
  
  
  METHODS
  Twelve patients presenting bilateral class II proximal furcation with vertical probing depth (PD) ≥5 mm and bleeding on probing were selected. The furcations were assigned to: a control group (n=12), open flap debridement (OFD)+EDTA and a test group (n=12) - OFD+EDTA+EMD. The gingival margin position, PD, relative vertical and horizontal clinical attachment level (RVCAL and RHCAL), vertical and horizontal bone level (VBL and HBL) and furcation closure were evaluated before treatment and after 6, 12 and 24 months.
  
  
  RESULTS
  After follow-up, no statistical difference could be seen between groups. At 24 months, the test group showed 1.9 ± 1.6 mm PD reduction whereas the control group showed 1.0 ± 1.3 mm PD reduction. RHCAL gains of the control and the test group were 0.7 ± 1.3 and 1.4 ± 0.9 mm, respectively. However, at 24 months, the test group only presented five remaining class II furcations versus 10 furcations in the control group (p<0.05).
  
  
  CONCLUSIONS
  It could be concluded that EMD therapy promoted a reduction in the number of proximal furcations presenting a diagnosis of class II after 24 months of treatment compared with OFD therapy.
authors.affiliation: Department of Prosthodontics and Periodontics, Division of Periodontics, School of Dentistry at Piracicaba, Campinas State University, São Paulo, Brazil.
authors.forename: Renato Corrêa Viana
authors.initials: RC
authors.lastname: Casarin
authors.forename: Erica Del Peloso
authors.initials: Edel P
authors.lastname: Ribeiro
authors.forename: Francisco Humberto
authors.initials: FH
authors.lastname: Nociti
authors.forename: Antônio Wilson
authors.initials: AW
authors.lastname: Sallum
authors.forename: Gláucia Maria Bovi
authors.initials: GM
authors.lastname: Ambrosano
authors.forename: Enilson Antônio
authors.initials: EA
authors.lastname: Sallum
authors.forename: Márcio Zaffalon
authors.initials: MZ
authors.lastname: Casati
mesh_terms: D000328:Adult; D016301:Alveolar Bone Loss / Q000601:surgery; D000539:Alveolar Process / Q000473:pathology; D001672:Biocompatible Materials / Q000627:therapeutic use*; D002614:Chelating Agents / Q000627:therapeutic use; D003646:Debridement; D003746:Dental Enamel Proteins / Q000627:therapeutic use*; D003774:Dental Plaque Index; D004311:Double-Blind Method; D004492:Edetic Acid / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D017823:Furcation Defects / Q000145:classification / Q000601:surgery*; D005881:Gingiva / Q000473:pathology; D005884:Gingival Hemorrhage / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D017622:Periodontal Attachment Loss / Q000601:surgery; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000601:surgery; D011446:Prospective Studies; D013524:Surgical Flaps; D014092:Tooth Root / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D001672:Biocompatible Materials; D002614:Chelating Agents; D003746:Dental Enamel Proteins; C109069:enamel matrix proteins; D004492:Edetic Acid